Indiana University

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Indiana University sits in the top decile of US sponsors by registered trial count (#38 of 15,742 sponsors by registered trial count).

890 total trials 156 currently recruiting 561 completed top decile by trial count

Indiana University: 890 sponsored US clinical trials, 156 recruiting.

Indiana University sponsors 890 registered US clinical trials on ClinicalTrials.gov, 156 of them currently recruiting, and 561 completed. 104 of these trials are in Phase 3-4 (later-stage) and 126 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alzheimer Disease, with 11 trials.

Top-decile sponsor footprint

Indiana University ranks in the top decile of sponsors by registered trial count (#38 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 43/100

561 of 688 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

890 total, page 14 of 18

COMPLETED Phase 4

Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress

NCT01585038

COMPLETED Phase 2

Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)

NCT01625845

COMPLETED NA

Exploring the Group Visit Model for Pediatric ADHD Management in the Medical Home

NCT02145793

COMPLETED NA

Role of Exercise in Depression in Middle Aged and Older Adults

NCT01573728

COMPLETED NA

Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging

NCT01673022

TERMINATED NA

Different Levels of Patient Education for Care of Ostomy Site

NCT02036268

COMPLETED NA

Child Health Improvement Through Computer Automation (CHICA) Highlighting Study

NCT01583101

COMPLETED NA

HealthyMe Online Weight Management Education/HealthyMe at Home

NCT02057952

COMPLETED Phase 3

Novel Use of (Oral) Ketotifen for the Treatment of Fibromyalgia: A Pilot Study

NCT01553318

COMPLETED NA

Very Low Calorie Diet for Diabetic Kidney Disease

NCT01671969

TERMINATED Phase 2

Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas

NCT01402817

COMPLETED

HPV Vaccine Acceptability Among Young Men Who Have Sex With Men

NCT01535794

TERMINATED Phase 1

Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)

NCT01489319

COMPLETED NA

Program ACTIVE II: Behavioral Depression Treatment for Type 2 Diabetes

NCT03371940

COMPLETED NA

Effect of a Component of Fish Oil on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma

NCT01504646

COMPLETED NA

A Self-Guided Intervention to Promote Condom Use Among African American Males

NCT01536730

COMPLETED NA

Evaluation of a New EUS-guided Needle (ProCore) Comparing to EUS-TCB Needle (Quick-Core)

NCT01768325

COMPLETED NA

Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake

NCT01232946

COMPLETED NA

Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control

NCT02002806

COMPLETED NA

Effectiveness of Prolonged Use of IUD/Implant for Contraception

NCT02267616

COMPLETED NA

Assessing the Effectiveness of a Weight Watchers-based Lifestyle Intervention for the Primary Prevention of Type 2 Diabetes

NCT02000024

COMPLETED

The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients

NCT00767897

TERMINATED NA

PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma

NCT01502228

TERMINATED Early Phase 1

Breast-Sparing Proton Therapy for Hodgkin's Disease

NCT02070393

COMPLETED NA

Trial of a Computer-Based Presentation of Quantitative Information About Colorectal Cancer Screening

NCT01415479

COMPLETED NA

Endotracheal Tube Versus Laryngeal Mask Airway for Esophagogastroduodenoscopy

NCT01936662

TERMINATED Phase 4

Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)

NCT01612884

COMPLETED Phase 2

Beating the Blues for Your Heart

NCT01605552

COMPLETED

Individualized Dosing of Nifedipine For Tocolysis in Preterm Labor

NCT02090920

COMPLETED NA

The CHICA Developmental Screening Study

NCT01351077

COMPLETED Phase 4

The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia

NCT01339858

COMPLETED

PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2)

NCT01536821

TERMINATED Phase 1

Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma

NCT01348503

COMPLETED NA

Narrow-Band Imaging Versus Standard White Light for the Detection of Serrated Lesions in the Proximal Colon

NCT01572428

COMPLETED

Bariatric Surgery and the Kidney

NCT01410994

COMPLETED Phase 4

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

NCT01270802

TERMINATED NA

Comparative Research of Alzheimer's Disease Drugs

NCT01362686

COMPLETED

Aqueous Suppressant Versus Aqueous Outflow on Ocular Blood Flow

NCT01308788

COMPLETED NA

Effect of Dermal Rejuvenation on the UVB Response of Geriatric Skin

NCT02090894

COMPLETED

A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies

NCT01319253

TERMINATED NA

The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux

NCT01317472

COMPLETED

Parent-son-provider Decision-making About HPV Vaccination

NCT01284374

COMPLETED Phase 1

A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer

NCT01265927

COMPLETED Early Phase 1

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

NCT01275586

COMPLETED Phase 3

Medication Reconciliation Technology to Improve Quality of Transitional Care

NCT01195051

COMPLETED NA

Effect of a Component of Fish Oil on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma

NCT01200446

TERMINATED

Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis

NCT01442454

TERMINATED Phase 2

Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)

NCT01212588

COMPLETED NA

Remote Information Counseling for Elders

NCT01203995

COMPLETED Phase 2

Acamprosate in Youth With Fragile X Syndrome

NCT01300923

← Previous Page 14 of 18 Next →

Phase Distribution

PhaseTrial count
Phase 1 56
Phase 2 70
Phase 3 28
Phase 4 76

What is open in the Indiana University pipeline

156 recruiting of 890 indexed (18% open); 561 completed (63%).

Phase mix: 104 late (III/IV) vs 126 early (I/II) (balanced across stages).

Top condition: Alzheimer Disease (11 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Indiana University: open-pipeline peers nationwide

Peers matched on 890 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Indiana UniversityUniversity of California, Los AngelesHoffmann-La RocheBrigham and Women's HospitalUniversity of Texas Southwestern Medical CenterEdwards LifesciencesUniversity of South FloridaVA Office of Research and DevelopmentConvaTec
Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 890 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this Indiana University page

890 registered trials is a research-attention snapshot, not an endorsement of Indiana University or any single study.

  • 156 of Indiana University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Alzheimer Disease is the condition Indiana University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alzheimer Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Indiana University pipeline card: 890 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.